Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
1. The safety and tolerability of single-dose of SCB-313 will be evaluated by
intraperitoneal injection;
2. The safety and tolerability of repeated-dose of SCB-313 will be evaluated by
intraperitoneal injection once a day for 3 days, and the maximum tolerated dose (MTD) of
SCB-313 will be determined;